The Coming Age of Personal Genetic Medicine
December 18, 2025 · Frisian News
Gene sequencing costs have fallen from millions to hundreds of dollars, pushing hospitals and clinics worldwide to adopt personalized treatment plans based on individual DNA. The shift promises better outcomes but raises tough questions about who pays, who has access, and who controls the data.
A cancer patient walked into her clinic with her personal genome report in hand. Her tumor DNA showed a mutation that made it vulnerable to a drug she had never heard of, one that standard treatment protocols would never have prescribed. She started the new drug, and her scans came back clear. That pattern repeats itself regularly now, across hospitals in Europe, Asia, and North America. The cost of full genome sequencing has fallen dramatically over recent decades, and that fall shows no sign of stopping.
Hospitals race to build genetic labs and hire specialists to read the data. Insurance companies struggle to decide which tests they will cover. Pharmaceutical firms retrain their entire sales teams because drugs no longer fit neat categories. A cancer drug that once targeted "breast cancer patients" now gets prescribed to women whose tumors carry a specific genetic fault, regardless of where the cancer started. The old approach, treating disease by what it looks like, dies fast. The new one treats disease by what it is made of at the molecular level.
Yet the shift creates sharp problems. In wealthy nations, genetic testing is becoming increasingly standard. In poor ones, patients never see it. A Somali farmer with the same cancer as that patient will likely never get her chance at that tailored drug. Even in rich countries, questions of power loom large. Who owns the genetic data? Tech firms and hospital networks already fight over ownership rights, and governments have not caught up with rules. If a company owns your genome, can it sell insights to insurers? Can police demand it without a warrant?
The science works. Survival rates jump when doctors use genetic data to pick drugs and doses. Costs fall over time as the technology matures. Yet access remains unequal and will stay that way for decades. A patient in rural Missouri will get less benefit from this revolution than a wealthy resident of London. The gap between those who can afford personal genetic medicine and those who cannot will grow before it shrinks.
Medicine in 2030 will look nothing like medicine in 2020. Doctors will treat individuals, not disease categories. The revolution is real and the benefits are real. But so is the risk that it becomes a luxury good, available to some and forbidden to others.
Published December 18, 2025 · Frisian News